Marco Pravetoni, PhD
The Pravetoni group focuses on development and translation of medical interventions against substance use disorders (SUD) and other chemical and biological threats. Current efforts are: 1) vaccines, monoclonal antibodies (mAb), and small molecules to treat or prevent SUD, opioid use disorders (OUD) and overdose, 2) mechanisms and biomarkers underlying or predicting efficacy of immunotherapeutics and medications in pre-clinical models of SUD and OUD patients, 3) novel strategies to enhance vaccine or medication efficacy, including immunomodulators, small molecules, adjuvants, nanoparticles, polymers and other delivery platforms, 4) Vaccines, mAb, and clinical biomarkers against infectious diseases (e.g., Pseudomonas aeruginosa and novel coronavirus SARS-CoV-2), 5) biosensors for field detection or diagnosis.
Education
PhD in Pharmacology, University of Minnesota, 2008
Department Affiliations
Scholarly Expertise
- Vaccines, monoclonal antibodies, immunology, pharmacology, chemical threats, immunoprofiling
Recent Publications
(2024 Nov)
PLoS Pathog 20(11): e1012515
Rollman TB, Berkebile ZW, Hicks DM, Hatfield JS, Chauhan P, Pravetoni M, Schleiss MR, Milligan GN, Morgan TK, Bierle CJ
(2024 Oct 15)
ACS Omega 9(41): 42506-42519
Rodarte J, Baehr C, Hicks D, McGovern M, Zhang Y, Silva-Ortiz P, Hannon B, Duddu S, Pancera M, Pravetoni M
(2024 Nov 15)
J Immunol 213(10): 1452-1466
Dick JK, Sangala JA, Krishna VD, Khaimraj A, Hamel L, Erickson SM, Hicks D, Soigner Y, Covill LE, Johnson AK, Ehrhardt MJ, Ernste K, Brodin P, Koup RA, Khaitan A, Baehr C, Thielen BK, Henzler CM, Skipper C, Miller JS, Bryceson YT, Wu J, John CC, Panoskaltsis-Mortari A, Orioles A, Steiner ME, Cheeran MCJ, Pravetoni M, Hart GT
(2025 Feb)
Biomaterials 313(): 122758
Walter DL, Bian Y, Hu H, Hamid FA, Rostamizadeh K, Vigliaturo JR, DeHority R, Ehrich M, Runyon S, Pravetoni M, Zhang C
(2024 Sep 1)
J Immunol 213(5): 663-668
Khaimraj A, Baehr CA, Hicks D, Raleigh MD, Pravetoni M
Show complete publication list »
